![](/img/cover-not-exists.png)
PCN207 COST COMPARISON OF ADVERSE EVENT MANAGEMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS OR CHEMOTHERAPY IN GBRCA-MUTATED, HER2-NEGATIVE ADVANCED BREAST CANCER (ABC): A US AND GERMAN HEALTHCARE PERSPECTIVE
McCrea, C., MacDonald, D., Hettle, R., McLaurin, K., Specht, A., Merens, C., Wynne, T.Volume:
22
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.403
Date:
November, 2019
File:
PDF, 321 KB
english, 2019